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Summary 
Several studies over the last few years have shown that newly arising (de novo) mutations 
contribute to the genetics of schizophrenia (SZ), autism (ASD) and other developmental disorders. 
The strongest evidence comes from studies of de novo Copy Number Variation (CNV), where the 
rate of new mutations is shown to be increased in cases when compared to controls [23, 24]. Research 
on de novo point mutations and small insertion-deletions (indels) has been more limited, but with 
the development of next-generation sequencing (NGS) technology, such studies are beginning to 
provide preliminary evidence that de novo single-nucleotide mutations (SNVs) might also increase 
risk of SZ and ASD [25, 26] 
 
Advanced paternal age is a major source of new mutations in human beings [27] and could thus be 
associated with increased risk for developing SZ, ASD or other developmental disorders. Indeed, 
advanced paternal age is found to be a risk factor for developing SZ and ASD in the offspring [28, 29] 
and new mutations related to advanced paternal age have been implicated as a cause of sporadic 
cases in several autosomal dominant diseases, some neurodevelopmental diseases, including SZ and 
ASD, and social functioning. New single-base substitutions occur at higher rates at males compared 
to females and this difference increases with paternal age. This is due to the fact that sperm cells go 
through a much higher number of cell divisions (~840 by the age of 50), which increases the risk for 
DNA copy errors in the male germ line [30] . By contrast, the female eggs (oocytes) undergo only 24 
cell divisions and all but the last occur during foetal life.  
 
The aim of my project is to determine the parent-of-origin of de novo SNVs, using large samples of 
parent-offspring trios affected with schizophrenia (SZ). From whole exome sequencing of 618 
Bulgarian proband-offspring trios affected, nearly 1000 de novo (SNVs or small indels) have been 
identified and from these, the parent-of-origin of at least 60% of the mutations (N=600) can be 
established.  This project is contained in a main one that consists on the determination of the 
parental origin of different types of de novo mutations (SNVs, small indels and large CNVs). 
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CHAPTER ONE: INTRODUCTION 
 
 
Neurological and mental disorders occur often, with approximately 450 million people suffering 
from them worldwide. According to the World Health Organization, mental and neurological 
diseases are responsible for approximately 1% of deaths and account for approximately 11% of the 
disease burden worldwide, a statistic that is expected to rise to 14.7% by the year 2020. Neurological 
and mental disease is a broad category covering a large number of disorders. The origins of these 
disorders, such as epilepsy, Schizophrenia, Alzheimer disease, Parkinson disease, cerebrovascular 
disease, depression, and brain cancer are difficult to determine. 
Like most other common diseases, neurological disorders are hypothesized to be highly complex, 
with interactions among genes and risk factors playing a major role in the process. Many rare 
mendelian genetic disorders, such as cystic fibrosis, are influenced by the effects of a single gene. 
Statistical methodologies were developed to detect these single-disease genes and were very 
successful. The problem is that these Methods were not developed in the context of detecting 
interactions among genes associated with common diseases.  
In recent years, it has become obvious that for common disorders, there may be more complex 
interactions among genes with and without strong independent main effects. These effects will be 
more difficult to detect using traditional methodologies. 
 
 
1.1 SCHIZOPHRENIA 
 
 
1.1.1 HISTORY 
 
Schizophrenia is a common and severe psychiatric disorder with a worldwide prevalence of 1%. 
Descriptions of schizophrenia can be found in works of literature from earliest written history. 
Schizophrenia-like symptoms are described in individuals labelled as seers and prophets, as well as 
devils and witches. An understanding of schizophrenia as a human brain disease did not develop 
until the 19th century, but it wasn’t until the middle of the 20th century that antipsychotic drug 
treatments became widely available [1]. 
 
It was first described in 1896 by Emil Kraepelin who used the term dementia praecox to distinguish 
this illness from manic depressive illness and dementia of the elderly [2].  Kraepelin further divided 
this patient group into three categories: hebephrenic, catatonic and paranoid. However, the term 
dementia praecox was thought by some to imply a pessimistic outcome in all cases and so, in 1908 
Eugen Bleuler introduced the term Schizophrenia which literary means splitting the mind [3]. This 
reclassification implied a disruption of usually integrated thought processes and feelings, and took 
into account the frequent partial or full social recovery seen in people diagnosed with schizophrenia.  
 
Now, at the beginning of the 21st century, there have been two generations of antipsychotic 
medications, several known risk genes, an evolving anatomy, but still no basic disease formulation.  
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1.1.2 SYMPTOMS 
 
The symptoms of schizophrenia are conventionally divided into two main categories, positive and 
negative. The positive symptoms can include hallucinations, both auditory and visual, delusions, 
thought disorder and bizarre behaviour. The negative symptoms, which reflect a loss of normal 
function, constitute emotional flattening, apathy, poor motivation and drive, impaired abstract 
reasoning and poor personal hygiene. This results in a deterioration of professional function and 
social withdrawal. Depressive symptoms are also common in schizophrenia patients although these 
are secondary [1].  
 
POSITIVE SYMPTOMS (psychotic symptoms)  
 
Hallucinations  
 Auditory > the most common type. More than 70 percent of patients (suggested by the IPSS) 
higher in industrialised societies, and up to 98percent in other studies. The voices have a 
negative content, patients will hear expletives, threats, demeaning personal comments, and 
accusations of vile thoughts or behaviours. Emotional experiences, most often sadness, often 
proceed hallucinations, but pacients also common experience the somatic symptoms of anxiety, 
and less frequently fear or anger, before the recurrence of hallucinations. Social stressors and 
physical illness and chronic pain, all can increase the frequency of hallucinations. 
 Visual> are less common than auditory, but they are not rare. They have a prevalence from to 
55 percent to one third of patients at some time of their illness. They have been suggested to 
predict a more severe illness. All kind of visual hallucinations have been described, from the 
most common ones, like images of animate objects, people, parts of people, religious images, 
fantastic creatures, inanimate objects like flashes of light, shadows,  to illusions (distortions of 
objects seen in the environment) and less often, distortion  of the world itself . 
The content of both auditory and visual hallucinations is often dependent on the culture of the 
person experiencing them. 
 Olfactory, gustatory and tactile> They are present in a range of 15 to 25 percent of patients. 
These hallucinations can take on a broad variety of forms; feelings on being touched, burned 
and cut are the most common; also sensations of electric shocks, tearing or stabbing; and the 
physical sense that somehow other people or magical beings enter into and exit their bodies. 
Olfactory and gustatory hallucinations are reported for a minority of patients. As with the other 
ones, the experience tends to be unpleasant, with smells of rotting meat, garbage and feces, 
and the taste of blood or metal frequently described. 
Delusions 
They are defined as a false belief based on incorrect inference about external reality that is firmly 
sustained despite what almost everyone believes and despite what constitutes incontrovertible and 
obvious proof of evidence to the contrary and not one ordinarily accepted by other members of the 
person’s culture. The delusions that are held by persons with schizophrenia are quite flexible, and 
can vary from fleeting concerns about personal meanings taken from the way a television news 
reader intonated a particular word, to a preoccupation with ideas about how giant corporations and 
governments are organised to persecute a particular person  with schizophrenia. Instead of arising 
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from a new kind of perception, delusions often arise from social stressors, and threats to self-esteem 
seem particularly prone to provoke persecutory or grandiose delusions in response. 
 
 
 
NEGATIVE SYMPTOMS 
 
Negative symptoms represent a loss or diminution of normal functions and stand in contrast to 
positive symptoms where there are perception, cognitions and behaviours added to normal mental 
functions.  It could be claimed that negative symptoms are the most important symptoms in 
schizophrenia because its severity  predicts long-term disability better than the severity of psychotic 
or disorganisation symptoms. 
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DISORGANIZATION 
 
The disorganization syndrome includes the formal thought disorder, bizarre and catatonic 
behaviours, inappropriate affect and attention impairments. It appears to be the most heritable of  
 
Motor symptoms  
 
Disturbance of motor activity seems to be most related to the disorganisation symptoms of 
schizophrenia, although some studies suggest that these symptoms are an independent dimension 
of psychopathology. Motor behaviours can include subtle repetitive hand movements or broad, 
complex, and purposeless movements that include limbs and trunk. Symptoms of catatonia are also 
included, although is important to note that catatonia may be as common in cases with brain injury 
and in psychotic mood disorders as it is in schizophrenia. It is suggested to be motor behaviour 
generated with a marked decrease in reactivity to the environment, and in its appearance it does 
suggest that central motor programmes are engaged without direction from frontal areas that direct 
higher level planning. 
 
Thought disorder 
 
It refers to the disorganisation of the form of thought, and not content. Speech is frequently stilted 
or vague, and sentences may be incomplete, it may be tangential, so that the associative chain 
moves obliquely off topic. With the progression of time, speech can further deteriorate, and 
inappropriate content can intrude. 
 
 
DEPRESSION AND ANXIETY 
 
Depression 
Most people with schizophrenia will experience a significant depression and anxiety during the 
course of their illness, and it has been claimed that depression is an integral part of the disorder. 
Clinicians and family may not notice depression or anxiety in their patients and relatives with 
schizophrenia, or may be too distracted by patient’s positive and negative symptoms. 
Anxiety 
Although is very prevalent, there is little known about anxiety in schizophrenia. Experience suggests 
that it can precipitate violence and suicidal ideation and that can lead to increases in psychosis and 
disorganization and depression. 
 
 
SUICIDE 
 
It accounts for a good part of the excess of mortality that is usually found in schizophrenia. From 20 
to 40 percent will make a suicide attempt sometime during their illness. Recent analysis suggests 
that 5 percent of the people with schizophrenia will commit suicide, with increased risk early in the 
course of illness [1]. 
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VIOLENCE 
 
For those with schizophrenia and their families and advocates, the real problem is that they are 
more likely to be victims of violence than the perpetrators. Although this is true, it also remains true 
that the evidence available indicates that a small percentage of people with schizophrenia will 
commit a disproportionate amount of violence and even murder.  
 
INSIGHT  
 
Lack of insight was the most common symptom of schizophrenia. It requires some ability to reflect 
on oneself, in parallel with a certainty about one’s existence and confidence in the limits of one’s 
being. Poor insight is associated with decreased compliance, worse overall function, increased levels 
of psychopathology, recurrent illness, and poor outcomes. 
 
 
 
1.1.3 DIAGNOSTIC 
 
There are no available biological markers or pathognomonic symptoms that can be used to diagnose 
an individual with schizophrenia and so a clinical diagnosis relies on behavioural observations and 
self reported abnormal experiences. Thus, there is a need for standardised procedures that a 
diagnostician can follow in order to make an accurate diagnosis. 
 
There have been changes in the diagnostic criteria of schizophrenia in order to uniform it, which will 
contribute to better communication among clinicians and researchers from different countries. 
Actually, the diagnostic criteria is based on the fifth version of the Diagnostic and Statistical Manual 
of Mental disorders (DSM-5) but before he DSM system was introduced, in 1980 the diagnosis of 
schizophrenia was highly subjective and early cross-national studies highlighted the international 
differences in the breadth and style of diagnosis [2] These differences led to many patients with 
manic-depressive illness being diagnosed with schizophrenia. 
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Until now, the DSM-IV-TR specified the criteria for diagnosis and therefore introduced a standard 
with which to train and guide diagnosticians worldwide. [4] The components of an individual’s illness 
can vary between cases. To allow for this phenotypic heterogeneity the DSM-IV-TR system 
categorised the symptoms into groups: Paranoid, Disorganised, Catatonic, Undifferentiated, Simple 
and Residual.  
This reflects the complex nature of the schizophrenic phenotype in that schizophrenia seems to 
affect a wide range of brain systems and produces diverse signs and symptoms but is clearly 
recognisable as a syndrome. 
 
The DSM is periodically reviewed and revised since it was first published in 1952. The previous 
version of DSM was completed nearly two decades ago; since that time, there has been a wealth of 
new research and knowledge about mental disorders. This May 2013 appeared the fifth edition of 
the DMS, with the following changes from DMS-IV. [16] 
 All subtypes of Schizophrenia were deleted (paranoid, disorganized, catatonic, 
undifferentiated, and residual). 
 A major mood episode is required for schizoaffective disorder (for a majority of the 
disorder's duration after criterion A is met). 
 Criteria for delusional disorder changed, and, in DSM-5, delusional disorder is no longer 
separate from shared delusional disorder. 
 In DSM-5, catatonia in all contexts requires 3 of a total of 12 symptoms. Catatonia may be a 
specifier for depressive, bipolar, and psychotic disorders; part of another medical condition; 
or another specified diagnosis. 
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1.2 CLINICAL EPIDEMIOLOGY OF SCHIZOPHRENIA 
 
 
1.2.1 INCIDENCE AND PREVALENCE  
 
Schizophrenia is a severe form of mental illness affecting about 7 per thousand of the adult 
population, mostly in the age group 15-35 years. Though the incidence is low (3-10,000), the 
prevalence is high due to chronicity. Schizophrenia Ranks among the top 10 causes of disability in 
developed countries worldwide. [5] 
 
To date, no population or culture has been 
identified in which schizophrenia does not occur.  
The rates of its occurrence are broadly 
comparable, but this does not imply that the 
incidence of the disorder is uniform across all 
populations. 
  
The incidence rate is the estimated annual 
number of first onset cases in a defined 
population per 1000 persons at risk, and the 
prevalence of the disease is the estimated 
number of cases per 1000 persons at risk in a 
population at a given time or over a defined 
period.  
 
 
Objective biomarkers of the disease process are still lacking, so onset is usually defined as the point 
in time when clinical manifestation become recognizable and can be diagnosed according to 
specified criteria. A systematic review of incidence data from some 160 studies in 33 countries, 
published between 1965 and 2001 estimated the median value of 0.15 and mean value of 0.24 per 
1000, with a fivefold range of the rates, and a tendency for recent studies to report lower rates. 
Since schizophrenia cases in prolonged remission are likely to be missed in point prevalence surveys, 
it will always be useful to estimate the lifetime prevalence by supplementing the assessment of the 
present mental state data with data about past episodes of the disorder.  A systematic review of 188 
studies in 46 countries, published between 1965 and 2002 estimated the median value for point 
prevalence at 4.6 per 1000 persons, and for lifetime prevalence at 7.2 per 1000.[1]  
 
[Note: The term 'prevalence' of Schizophrenia usually refers to the estimated population of people who are 
living with Schizophrenia at any given time. The term 'incidence' of Schizophrenia refers to the annual 
diagnosis rate, or the number of new cases of Schizophrenia diagnosed each year. ] 
 
 
The global distribution of schizophrenia according to 
WHO  (World Health Organisation) 2002 
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The prevalence of schizophrenia compared to other well-known diseases. 
 
 
 Schizophrenia affects about 24 million people worldwide. 
 Schizophrenia is a treatable disorder, treatment being more effective in its initial stages. 
 More than 50% of persons with schizophrenia are not receiving appropriate care. 
 90% of people with untreated schizophrenia are in developing countries. 
 Care of persons with schizophrenia can be provided at community level, with active family 
and community involvement.  
There are effective interventions (pharmacological and psychosocial) available and the cost of 
treatment of a person suffering from chronic schizophrenia is about US$2 per month; the earlier the 
treatment is initiated, the more effective it will be. However, the majority of the persons with 
chronic schizophrenia do not receive treatment, which contributes to the chronicity. [6] 
 
 
 
1.2.2 FACTORS INFLUENCING THE VARIATIONS IN OUTCOME 
 
 
The outcome of schizophrenia is a result of a genetic predisposition combined with an 
environmental exposures and / or stresses during pregnancy or childhood that contribute to, or 
trigger, the disorder. Already researchers have identified several of the key genes - that when 
damaged - seem to create a predisposition, or increased risk, for schizophrenia. The genes, in 
combination with suspected environmental factors are believed to be the factors that result in 
schizophrenia. These genes that seem to cause increased risk of schizophrenia include the DISC1, 
Dysbindin, Neuregulin and G72 genes,  but it has been estimated that up a dozen or more genes 
could be involved in schizophrenia risk.  
 
One of the most positive areas of schizophrenia research today is in the area of identification of 
early risk factors for development of schizophrenia, and prevention of schizophrenia in those people 
who are predisposed to the disease.  
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The risk of getting schizophrenia. After a person has been diagnosed with schizophrenia in a family, the chance 
for a sibling to also be diagnosed with schizophrenia is 7 to 9 percent. If a parent has schizophrenia, the chance 
for a child to have the disorder is 10 to 15 percent. Risks increase with multiple affected family members. 
[7] 
 
 
1.2.3 THE BURDEN OF COMORBIDITY 
 
There is a significant comorbidity in schizophrenia, comprised mainly of common diseases that affect 
schizophrenic patients more frequently than attributable to chance, as well as certain rare 
conditions or abnormalities which tend to co-occur with the disorder. Persons with schizophrenia, 
especially those who are homeless or injection drug users, are at increased risk for potentially life-
threatening communicable diseases, such as HIV/AIDS, hepatitis C, and tuberculosis. Among the 
chronic no communicable diseases, they have higher rates than expected rates of epilepsy, diabetes, 
arteriosclerosis, and ischemic heart disease. Obesity and the concomitant metabolic syndrome 
involving insulin resistance are becoming increasingly common problems in schizophrenic patients.  
Moreover, certain genetic or idiopathic disorders have been reported to co-occur with 
schizophrenia.  
 
Substance abuse is at the present by far the most common associated health problem among 
patients with schizophrenia, and may involve any drug abuse or a polydrug combination. The 
addictive use of cannabis, stimulants, and nicotine is disproportionately high among schizophrenic 
patients and may be related to the underlying neurobiology of disorder. Early use of cannabis 
increased the risk of psychosis in a dose-related manner, especially in persons at high genetic risk of 
schizophrenia. [1] 
 
 
1.2.4 RISK FACTORS OF THE ONSET OF SCHIZOPHRENIA 
 
 
There are several risk factors operating during early development involved in the onset of 
schizophrenia, among them, the risk factor related with the paternal age is relevant for this project. 
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Paternal age 
Large population based cohort studies from Israel, the United States, Denmark and Sweden, 
provided strong evidence consistently linking advanced paternal age to the risk of schizophrenia in 
the offspring. There is a higher risk in schizophrenia (around three to four times) in the offspring of 
fathers who are older than 50 at the time of conception, compared to the offspring of fathers in 
their early 20s. 
In evidence on gene environment interactions, there is a stronger association between paternal age 
and schizophrenia in people without a family history. This observed pattern of effect lends support 
for two genetic theories. The first and most likely is that advancing paternal age results in 
accumulation of de novo mutations in the germ cells of older fathers, or second, advancing 
paternal age interferes with the DNA-methylation process of gene expression. 
 
Season of birth 
Winter birth, in people who later develop schizophrenia is a robust epidemiological finding, at least 
in the northern hemisphere. It is likely to be a proxy indicator for some seasonally fluctuating 
environmental factor. The most popular hypothesis relate to seasonal variation in exposure to 
intrauterine viral infections around the time of birth, or variation in light, temperature/weather, or 
external toxins.  
 
Pregnancy and birth complications 
The literature suggests that pregnancy and birth complications can have a small effect on the risk of 
later development of schizophrenia, as it has been demonstrated in a large number of published 
studies. Investigators found three main categories of obstetric complications to have significant 
estimates: 
 Abnormal fetal growth and development: low birth weight, congenital malformations, and 
small head circumference. 
 Complications of pregnancy: bleeding, pre-eclampsia, diabetes, and rhesus incompatibility. 
 Complications of delivery: Asphyxia, uterine-atony, and emergency caesarean section. Taken 
together, they seem to implicate an increased risk of hypoxia. 
 
Other putative prenatal risk factors 
A study from New York City found a 10 to 20 percent increased risk for schizophrenia in people who 
had serologically confirmed prenatal rubella exposure, while further studies have implicated 
prenatal exposure to toxoplasmosis, poliovirus, and other common respiratory infections. It has 
been suggested that the effect may be in part due to cytokines and chemokines, which mediated 
host response to infection.  There is some evidence that maternal-fetal genotype incompatibility 
effects increases the risk of developing schizophrenia.  
There might be higher rates of schizophrenia in the offspring of mothers who experienced significant 
levels of stress during pregnancy, such as the death of a spouse or living through a natural disaster 
or military invasions. Nutritional deficiency in pregnancy may also increase the risk. [1] 
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1.3 GENETIC EPIDEMIOLOGY OF SCHIZOPHRENIA 
 
 
1.3.1 FAMILY STUDIES 
 
In order to determine if susceptibility to schizophrenia involves a genetic component, it is essential 
to first demonstrate whether the illness is clustered within affected families. This can be quantified 
by estimating the risk of developing the disease in different classes of relative and determining 
whether this is greater than the population average.  
 
Overall both the old and new family studies established the high familial loading of schizophrenia, 
with siblings consistently showing about eight- to tenfold increased risk of being ill, compared with 
the rest of the general population. This is much greater than the risk reported for any environmental 
factor studied. 
If a condition is found to be more common in relatives of probands, this could be due to shared 
genes or to shared environmental factors. Therefore, in order to confirm that a disorder is genetic, 
other types of studies need to be conducted, such as twin and/or adoption studies, which control for 
the environmental factors. 
 
 
1.3.2 TWIN STUDIES 
 
Following the demonstration of familial clustering, twin studies have been used to determine 
whether this is due to genetic factors or is the result of shared environmental factors. The rationale 
behind twin studies is that if a disease is caused predominantly by genetic factors, then it would be 
expected that concordance rates between MZ twins (who share 100% of their DNA) would be 
greater than DZ twins (who on average share 50% of their DNA). Conversely, if the disease is caused 
by environmental factors, then the rate of concordance between MZ and DZ twins would be the 
same assuming that both types of twin share environmental influences to the same extent .  
The concordance rate refers to the proportion of co-twins who are also affected, or the proportion 
of twin pairs where both twins are affected. 
 
After comparing different studies, it is clear that schizophrenia occurs more frequently in the 
relatives of patients, and that MZ concordance is greater than DZ concordance. These findings could 
still be explained to some extent by shared environmental factors. One way to control for them is 
provided by adoption studies.  
 
 
1.3.3 ADOPTION STUDIES 
 
Although family and twin studies have shown that schizophrenia aggregates within families there is 
always the possibility that this clustering may be the result of a shared familial environment. In order 
to clarify this problem adoption studies have been used. The general principle behind adoption 
studies is that if there is a genetic component to the disorder studied, the similarity between 
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adopted children and their biological parents should be higher than the similarity between adopted 
children and their adoptive parents. 
In the different studies performed, a much higher rate of illness was found in children whose 
biological parents had schizophrenia. 
 
All adoption studies come to remarkably conclusions: children of schizophrenic parents have a risk of 
developing schizophrenia, schizoaffective disorder, or other narrow spectrum schizophrenic 
disorders of at least 10 percent, even when they are adopted away very soon after birth. The risk is 
very similar to the risk among children with schizophrenic parents reported in family studies, 
suggesting that most of the transmission is genetic, rather than an effect of upbringing. This high 
risk was not due to the stress of adoption either, as several studies had control samples of adoptees 
of normal parents, where the risk of narrow spectrum schizophrenia was 0 to 2 percent (similar to 
the population risk). [1] 
Adoption studies have therefore convincingly supported the results of family and twins studies in 
demonstrating the significant role of genetic factors in schizophrenia. 
 
 
1.3.4 WHAT IS INHERITED? 
 
The evidence from family, twin and adoption studies clearly implicates an important genetic 
contribution to schizophrenia. However the facts that no study has found MZ twins are 100% 
concordant suggest environmental factors play a role and that the mode of inheritance, like that of 
other common disorders, is complex and non-Mendelian.  
 
Genetic epidemiologists suggest that the genes that predispose to schizophrenia do not respect the 
diagnostic categories used by psychiatrists. There is good evidence for a spectrum of milder 
phenotypes associated with risk to schizophrenia, the so called extended phenotype, and also that 
there is an overlapping risks with other disorders, in particular bipolar disorder. 
The fact that the risk of schizophrenia among relatives is much smaller than what would be expected 
from a genetic disorder has troubled many schizophrenia researchers. On the other hand, it has 
been observed that although some do not meet the diagnostic criteria for the disorder, some of 
their relatives exhibit a certain degree of psychopathology, which could be explained as a variable 
penetrance of the disease genes, called at the beginning of the 20th century as “latent 
schizophrenia”. 
It appears that what is transmitted in families is a liability to develop not only schizophrenia, but also 
schizotypal and paranoid personality disorders and other psychotic illnesses. 
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1.4 MAPING COMPLEX TRAITS 
 
 
1.4.1 LINKAGE STUDIES 
 
There are two main strategies to find specific genes that cause schizophrenia: Linkage and 
association studies. A third strategy emerged more recently: searching for copy number variation 
(CNV). 
Linkage studies make no assumption about specific genes involved in the ethiology of the disorder, 
while until recently association studies had focussed on candidate genes. Recently, linkage studies 
have been followed by association studies of the genes contained within the chromosomal regions 
implicated and have produced some of the more replicated findings. The availability of array-based 
single-nucleotide polymorphism (SNP) genotyping, has allowed association studies to start targeting 
the whole genome. 
 
Linkage studies in schizophrenia have been reviewed many times over the years and subjected to 
several meta-analyses. There have been at least 27 whole genome studies that analysed between 1 
to 294 pedigrees containing between 32 and 669 individuals affected with a narrow definition of 
schizophrenia. These studies have been based on very different sample sizes, with correspondingly 
different statistical power, and they used different methods and different quality controls. Several 
meta-analyses have reached somewhat different conclusions. Large numbers of genes were 
implicated and a few genes were consistently identified in more than a small subset of studies.  
 
The first conclusions that can be drawn is that no single gene for schizophrenia exists, confirming 
that is not a single gene disorder. Several genomic loci have received support from several studies. 
There are two explanations why the studies so far have produced such different linkage findings. 
 Different genes operate in different populations. 
 Schizophrenia is caused by the effect of many genes of small effect, so that the studies had 
no power to detect the loci. It has been estimated that 4900 pedigrees would be required to 
have 80 percent power to detect a locus accounting for 5 percent of variance in liability to 
schizophrenia at α=0.001. [1] 
 
 
1.4.2 MODE OF INHERITANCE 
 
The inability of linkage studies to unambiguously identify linkage signals and the absence of a clear 
mode of transmission in the vast majority of families affected with schizophrenia indicates that this 
is not a simple Mendelian disorder, but a disorder of complex inheritance.  
There are two main hypotheses about the genetic background of common diseases (including 
schizophrenia):  
 The common disease/common variant (CDCV) hypothesis proposes that common diseases 
are caused by common variants.  This model suggests a joint action of several common 
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genetic variants, each of which has a small effect on illness susceptibility, together with the 
environmental factors. 
 The rare variants hypothesis postulates that multiple rare variants in different gens, which 
have low population frequencies, operate in different individuals 
However, it is most likely that both mechanisms operate in common diseases, including 
schizophrenia, as both high and low-frequency alleles have been found to contribute to several 
common diseases.  There are rare chromosomal aberrations that appear to have a high penetrance 
and cause a small number of cases of schizophrenia. 
 
 
1.4.3 ASSOCIATION STUDIES 
 
Several teams followed their positive linkage findings with fine mapping association studies of genes 
in linked chromosomal regions and identified the most plausible candidates to date. 
 
 Dystrobrevin-Binding Protein 1 (DTNBP1) 
Dysbindin binds both α and β-dystrobrevin, which are components of the dystrophin glycoprotein 
complex, located in both the sarcolemma of muscle and the brain. Konrad Talbot end colleagues 
found that the presynaptic dystrobrevin-independent fraction of dysbindin is reduced in 
schizophrenic brain within certain glutamatergic neurones of the hippocampus, and this is 
associated with increased expression of vesicular glutamate transporter type 1. Moreover, a 
reduction in glutamate release has been demonstrated in cultured neurons with reduced DTNBP1 
expression.  Variations in DTNBP1 might confer risk by altering presynaptic glutamate function. 
 
 Neuregulin 1 (NRG1) 
It encodes multiple proteins with a diverse range of functions in the brain, including cell-cell 
signalling, ErbB receptor interactions, axon guidance, synaptogenesis, glial differentiation, 
myelination, and neurotransmission. Any of these could potentially influence the susceptibility of 
schizophrenia. 
 
Other candidate genes are: DAOA, G72/G30, COMT, RGS4, CAPON, PRODH and AKT1, but their 
status remains uncertain. [1] 
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1.5 GENETIC ARCHITECTURE OF SCHIZOPHRENIA 
 
 
Although a genetic component of schizophrenia has been acknowledged for a long time, the 
underlying architecture of the genetic risk remains a contentious issue. Early linkage and candidate 
association studies led to largely inconclusive results. More recently, the availability of powerful 
technologies, samples of sufficient sizes, and genome-wide panels of genetic markers facilitated 
systematic and agnostic scans throughout the genome for either common or rare disease risk 
variants of small or large effect size, respectively. Although the former had limited success, the role 
of rare genetic events, such as copy-number variants (CNVs) or rare point mutations, has become 
increasingly important in gene discovery for schizophrenia. Importantly, recent research building 
upon earlier findings of de novo recurrent CNVs at the 22q11.2 locus, has highlighted a de novo 
mutational paradigm as a major component of the genetic architecture of schizophrenia. Recent 
progress is bringing us closer to earlier intervention and new therapeutic targets.[8]  
 
 
1.5.1 GENOME WIDE ASSOCIATION STUDIES 
 
 
A genome-wide association study is an approach that involves rapidly scanning markers across the 
complete sets of DNA, or genomes, of many people to find genetic variations associated with a 
particular disease. Once new genetic associations are identified, researchers can use the information 
to develop better strategies to detect, treat and prevent the disease. Such studies are particularly 
useful in finding genetic variations that contribute to common, complex diseases, such as asthma, 
cancer, diabetes, heart disease and mental illnesses. 
 
With the completion of the Human Genome Project in 2003 and the International Hap Map Project 
in 2005, researchers now have a set of research tools that make it possible to find the genetic 
contributions to common diseases. The tools include computerized databases that contain the 
reference human genome sequence, a map of human genetic variation and a set of new 
technologies that can quickly and accurately analyze whole-genome samples for genetic variations 
that contribute to the onset of a disease.[21] 
 
Technological advances in SNP genotyping made such studies feasible. Two companies, Affymetrix 
ad Illumina, designed microarrays that are capable of simultaneously genotyping hundreds of 
thousands of SNPs on a single array. 
To carry out a genome-wide association study, researchers use two groups of participants: people 
with the disease being studied and similar people without the disease. Researchers obtain DNA from 
each participant which is then purified, placed on tiny chips and scanned on automated laboratory 
machines. The machines quickly survey each participant's genome for strategically selected markers 
of genetic variation, which are called single nucleotide polymorphisms, or SNPs.  
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If certain genetic variations are found to be significantly more frequent in people with the disease 
compared to people without disease, the variations are said to be "associated" with the disease. The 
associated genetic variations can serve as powerful pointers to the region of the human genome 
where the disease-causing problem resides. However, the associated variants themselves may not 
directly cause the disease. They may just be "tagging along" with the actual causal variants. For this 
reason, researchers often need to take additional steps, such as sequencing DNA base pairs in that 
particular region of the genome, to identify the exact genetic change involved in the disease. [21] 
Availability of next-generation whole-genome or whole-exome sequencing now permits the study 
of de novo mutations (point substitutions or single nucleotide variants (SNVs) and small insertions 
or deletions (indels)) in a systematic genome-wide manner [17,18] 
Pilot studies focusing on specific synaptic genes identified a small number of putative de novo 
mutations in individuals with schizophrenia[19]. However, the full contribution of rare de novo SNVs 
and indels to schizophrenia remains unknown. 
 
 
1.5.2 CNV : COPY NUMBER VARIATION 
 
 
In order to identify the genetic variants that increase susceptibility to schizophrenia, it appears clear 
that SNV will not account for all the genetic susceptibility, and that there is a need to explore other 
sources of genetic variability. Therefore, the structural variation in human chromosomes is the most 
promising, as large chromosomal aberrations can cause several neurodevelopmental disorders, 
disrupting gene function, inactivating, or even duplicating genes. Technological advances have 
recently enabled the use of high resolution techniques, which have been instrumental in identifying 
up to 20 percent of sufferers with mental retardation and autism, where most of the chromosomal 
changes  that appear causative have arisen de novo, such as spontaneous mutations in the parental 
germ cells.  
Schizophrenia has certain features that suggest a partial overlapping etiology with mental 
retardation and autism, including a tendency to show delayed development and lower intelligence 
quotient, language and communication problems, and a higher rate of minor physical anomalies. 
There have been many numerous reports associating schizophrenia and large chromosomal 
abnormalities, two of them providing convincing evidence for the location of a susceptibility gene. 
 
 Chromosome 22q11.2 Deletion Syndrome 
The first and best replicated finding of a chromosomal aberration that increases the risk of 
schizophrenia is a homozygous deletion of chromosome 22q11.2, also known as 
DiGeorge/velocardiofacial syndrome (VCFS). The prevalence of this syndrome has been estimated at 
between 1 in 3.900 to 1 in 9.700 children. [1]  Carriers of the deletion present with enormous 
phenotypic heterogeneity, with the most common features being cardiac anomalies, hypocalcemia, 
cleft lip/palate, renal abnormalities, skeletal abnormalities, developmental delay, especially speech 
delay, and behavioural and psychiatric disorders.  
The deletion is caused by the presence of four blocks of low copy number repeats (LCRs) in this 
region, named LCR A-D, which are larger, more complex and have a higher homology than any other 
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LCRs in the human genome. The deletion affects typically a 3-Mb region, although a tenth of cases 
are caused by a smaller deletion, and at least 35 genes are present within the commonly deleted 
region. 
Most commonly is presented as de novo mutation, but between 8 and 28 percent of cases is 
inherited from parents who have a mild phenotype. 
Several studies have shown that adults with 22q11.2 deletions have a high risk of schizophrenia, as 
the deletion accounts for up to 3 to 6 percent of the cases with schizophrenia. 
Reports on linkage to 22q11 suggest that variants in genes mapping to this region might contribute 
to cases of schizophrenia that do not have 22q11 deletions. One good candidate gene in the region 
appears to be catecholamine-O-methyl transferase (COMT), and evidence in favour of a role in 
schizophrenia susceptibility has been reported for several other genes including TBX1, GNB1L, 
PRODH and ZDHHC, although there is no compelling evidence yet. It remains possible that the high 
risk for schizophrenia resulting from these deletions, reflect haploinsufficiency of more than a single 
gene. 
 
 DISC1 
The other major finding on a chromosomal abnormality comes from a balanced chromosomal 
translocation (1,11) (q42, q14.3) that showed very strong evidence for linkage to a fairly broad 
phenotype consisting of schizophrenia, bipolar disorder and recurrent depression. The translocation 
was found to disrupt two genes on chromosome 1: DISC1 and DISC2. DISC2 contains no open 
reading frame and may regulate DISC1 expression by antisense RNA. It has been suggested that the 
disruption of DISC1 might contribute to schizophrenia by affecting neuronal functions dependent on 
intact cytoskeletal regulation, such as neuronal migration, neurite architecture, and intracellular 
transport. [1] 
At the moment, there are suggestions that DISC1 variants might confer susceptibility to a range of 
phenotypes, including schizoaffective disorder, bipolar disorder, and recurrent major depressive 
disorder as well as schizophrenia. 
 
Genome structural variation has been known for a long time, but its extent was not appreciated until 
recently. The earlier technologies available allowed us to improve in these studies. Is known that 
every person in the general population carries a surprisingly large number of such CNVs, many of 
which involved single-copy genes. Despite this, very few disorders have been associated with CNVs, 
but the list is expected to rise. Several studies have been published, and analysis of data reported 
indicates that some CNVs shown to contribute towards the pathogenesis of autism are also involved 
in schizophrenia. These findings demonstrate the important role of structural chromosomal variation 
in the pathogenesis of the disorder, and bring hope that other smaller or rarer CNVs will be 
identified soon, when more samples are investigated, and even higher-resolution platforms become 
available. 
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1.6 DE NOVO MUTATIONS 
 
 
De novo mutations are mutations observed in a child but not in his or her parents, and they are 
assumed to have occurred in one of the parental germ lines. 
 
All genetic variation arises via new mutations; therefore, determining the rate and biases for 
different classes of mutation is essential for understanding the genetics of human disease and 
evolution. Recent studies have shown that 76% of new mutations originate in the paternal lineage 
and provide unequivocal evidence for an increase in mutation with paternal age. Although most 
analyses have focused on single nucleotide variants (SNVs), studies have begun to provide insight 
into the mutation rate for other classes of variation, including copy number variants (CNVs), 
microsatellites, and mobile element insertions (MEIs).[9]  
 
The replication of the genome before cell division is a remarkably precise process. Nevertheless, 
there are some errors during DNA replication that lead to new mutations. If these errors occur in the 
germ cell lineage (i.e., the sperm and egg), then these mutations can be transmitted to offspring. 
Some of these new genetic variants will be deleterious to the organism, and a select few will be 
advantageous and serve as substrates for selection. There-fore, knowledge about the rate at which 
new mutations appear and the properties of new mutations is critical in the study of human genetics 
from evolution to disease. 
 
Over the past few years, it has become feasible to generate large amounts of sequence data 
(including the genomes of parents and their offspring), and it is now possible to calculate empirically 
a genome-wide mutation rate. In addition, much interest has focused on under-standing the role of 
de novo mutations in human disease. 
 
Recent genome-wide studies (on all individuals from a nuclear family) of the SNV mutation rate in 
humans have started to converge. These studies based on whole-genome sequencing and direct 
estimates of de novo mutations give an average SNV mutation rate of 1.16*10-8 mutations per base 
pair per generation [95% confidence interval (CI) of the mean: 1.11–1.22] in 96 total families. [10-14]  
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1.6.1 DE NOVO MUTATIONS IN SCHIZOPHRENIA 
 
 
Schizophrenia has a strong genetic component. However, despite its high heritability, a large fraction 
of individuals with schizophrenia do not have a family history of the disease[22]. Although largely 
ignored in earlier efforts to model disease risk, de novo germ line mutations may account for a 
substantial fraction of sporadic schizophrenia cases. 
 
Several studies in the last 5 years have shown that newly arising (de novo) mutations contribute to 
the genetics of schizophrenia (SZ). This will replenish genetic variants removed by natural selection 
and could, in part, explain why SZ prevalence has remained stable in the general population despite 
low fecundity. The strongest evidence to date for the association between SZ and de novo mutation 
comes from studies of de novo copy number variation (CNV), where the rate of de novo CNV 
mutation is shown to be increased in cases when compared with controls, and genes disrupted by 
these mutations are enriched for those encoding proteins involved in synaptic function and 
development. [15] Recent studies involving next-generation sequencing technology have provided 
preliminary evidence that de novo single-nucleotide mutations might also increase risk of SZ.  
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CHAPTER TWO: IDENTIFYING THE PARENT OF ORIGIN OF DE NOVO SNVS IN 
SCHIZOPHRENIA 
 
 
 
2.1 BACKGROUND 
 
 
Several studies over the last few years have shown that newly arising (de novo) mutations 
contribute to the genetics of schizophrenia (SZ), autism (ASD) and other developmental disorders. 
The strongest evidence comes from studies of de novo Copy Number Variation (CNV), where the 
rate of new mutations is shown to be increased in cases when compared to controls [23, 24] 
Research on de novo point mutations and small insertion-deletions (indels) has been more limited, 
but with the development of next-generation sequencing (NGS) technology, such studies are 
beginning to provide preliminary evidence that de novo single-nucleotide mutations (SNVs) might 
also increase risk of SZ and ASD [25, 26] 
While the extent of involvement of de novo mutations is currently unknown, the evidence for their 
involvement offers a new approach to detect potentially pathogenic variants and may help to 
explain partially the causes and inheritance pattern of SZ and also how SZ prevalence remains stable 
in the general population despite low fecundity.  
 
Advanced paternal age is a major source of new mutations in human beings [27] and could thus be 
associated with increased risk for developing SZ, ASD or other developmental disorders. Indeed, 
advanced paternal age is found to be a risk factor for developing SZ and ASD in the offspring [28, 29] 
and new mutations related to advanced paternal age have been implicated as a cause of sporadic 
cases in several autosomal dominant diseases, some neurodevelopmental diseases, including SZ and 
ASD, and social functioning.   
 
New single-base substitutions occur at higher rates at males compared to females and this 
difference increases with paternal age. This is due to the fact that sperm cells go through a much 
higher number of cell divisions (~840 by the age of 50), which increases the risk for DNA copy errors 
in the male germ line [30] . By contrast, the female eggs (oocytes) undergo only 24 cell divisions and all 
but the last occur during foetal life.  
 
Much less is known about the parent-of-origin and the effect of increased parental age on the 
genesis of CNVs. A recent study on mental retardation found de novo CNVs to be mostly of paternal 
origin and to be associated with increased paternal age[31]. This was particularly evident for non-
recurrent CNVs that arise by replication based mechanisms such as non-homologous end joining 
(NHEJ) or microhomology-mediated break-induced repair (MMBIR). By contrast, recurrent de novo 
CNVs are often flanked by segmental duplications that mediate the generation of these 
rearrangements through non-allelic homologous recombination (NAHR) mechanism which may be 
similar during both paternal and maternal meiosis. No parent-of-origin or parental-age effect has 
been demonstrated for this class of CNVs, which occur relatively frequently and recur because of the 
predisposing chromosomal architecture [31, 32]. 
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The widespread use of high resolution genomic microarrays and whole genome NGS has now made 
possible the analyses of rare de novo mutations (from SNVs and small indels to large-scale CNVs). 
Currently only few studies have been able to determine the parent-of-origin of de novo mutations. 
Overall, de novo mutations are more frequent in SZ and ASD patients than in normal individuals 
and the mutational burden increases with paternal age [33].  
 
De novo point mutations are predominantly paternal in origin and positively correlated with 
paternal age at the time of conception of the child [26, 29, 34]. These results are very encouraging, 
however, the number of families analysed so far is too small to draw definitive conclusions about the 
correlation with maternal age, and whether the paternal effect is the same for single substitutions, 
small indels and large CNVs.  
 
 
2.1.1 THE AIM OF THE PROJECT 
 
The aim of the project is to determine the parent-of-origin of de novo SNVs, using large samples of 
parent-offspring trios affected with schizophrenia (SZ).   This project is contained in the main one 
that consists on the determination of the parental origin of different types of de novo mutations 
(SNVs, small indels and large CNVs) using large samples of parent-offspring trios affected with 
schizophrenia  or bipolar affective disorder. 
 
 
 
2.2 SAMPLE DESCRIPTION AND DATASETS USED FOR DE NOVO SNVS DETECTION 
 
 
 
The department where I am doing my final project is leading a whole exome sequencing project of 
618 Bulgarian proband-offspring trios affected with SZ. Nearly 1000 de novo mutations (SNVs or 
small indels) have been identified and 430 of those are predicted to change the amino-acid 
sequence. About 90% of high-quality calls for non-synonymous and synonymous mutations have 
been confirmed with Sanger sequencing of the trios.  
 
The first steps of the project before I came involved: from DNA collection, to validation of the called  
de novo SNV with Sanger sequencing. And with that they obtained around 650 coding and 450 non-
coding de novo mutations for analysis. From these, the parent-of-origin of at least 60% of the 
mutations (N=600) can be established.  
 
 
 
Laura Escudero Monreal        IDENTIFYING THE PARENT-OF-ORIGIN OF DE NOVO SNVs IN SCHIZOPHRENIA  
 
 
26 
 
 
2.3 DETERMINING THE PARENT OF ORIGIN OF DE NOVO SNVS 
 
 
 
The aim of the project is to find the parental origin of de novo mutations (not inherited).They could 
be originated in the oogenesis (mother) or what is thought to be more likely, in the spermatogenesis 
(father). In order to prove it, an informative SNP near each de novo SNV will be selected, and the 
child and parents genotype looked (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
So, the first part of the project consisted on explore the NGS runs and the Affymetrix 6.0 data for the 
presence of other inherited informative SNPs in close proximity (within ~5000bp) of the de novo 
mutation, that lie (or don’t lie) on the same sequence read (or pair-end read) with the mutation 
(Table 2). If the de novo mutation is on the same read as the inherited mutation, then it has 
occurred in the parent who transmitted it (and vice versa) (Figure 1).  
The method works only if the proxy SNP is informative, which means that the child is heterozygous, 
and the parents are either homozygous for the alternative alleles, or only one of them is 
heterozygous for the transmitted SNP. 
 
 
 
Chr POSITION REF ALT GENE SAMPLE ID CHILD-META PAT-META MAT-META 
de novo  
SNV 
1 151028149 T A CDC42SE1 1402-1 [AD=6,7] [AD=21,0] [AD=17,0] 
proxy  
SNP 
1 151026815 C T CDC42SE1 1402-1 0/1 1/1 0/1 
 
 
 
 
Once the list of all the de novo SNV, each with its informative SNP, was created, groups were made 
depending on the distance between the de novo and the proxy (within 1kb, 2kb, 3 kb,...), as the PCR 
conditions were going to be different depending on the size.  And then, the primers for the first, 
second, third and the fourth set were designed. For each couple (proxy SNP + de novo SNV) a 
Forward and a Reverse primer for the 1st PCR, and then allele-specific primers for the 2nd PCR (using 
the Forward or Reverse from the 1st PCR) was needed. 
 de novo SNV SNP near the SNV 
Child C/T A/G 
Father T/T A/G 
Mother T/T G/G 
 
 
 
x 
T
A 
T
G 
FATHER 
T
G 
T
G 
MOTHER 
C
A 
T
G 
CHILD 
Table 1. The genotype of the parents and the chid is 
showed. The child presents the allele C as the de novo 
mutation. The parents present an informative SNP 
(Heterozygous for the child and the father, and 
homozygous for the mother). 
Figure 1.  
The de novo SNV 
(C) is transmitted 
from the father. 
We can see how 
is in the same 
chromosome as 
the allele A 
(father) of the 
informative SNP. 
Table 2. Information of the position in the chromosome, the reference and the alternative alleles, the gene, the sample id, 
and the genotype of the child, and the parents for the de novo SNV with its proxy SNP is showed.   
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Once the primers arrived, the laboratory work consisted on the method based on allele-specific 
Polymerase Chain Reaction (PCR) of the inherited SNPs that lie within ~5000bp away from a de novo 
mutation, to establish again whether the inherited SNP was on the same DNA strand as the 
mutation.  
 
Briefly, the method included two-stage PCR. In the first stage a PCR product that encompasses both 
the de novo mutation and the inherited SNP was obtained (PCR1). This product was used for allele-
specific PCR (PCR2) using two allele-specific primers, each complementary to the alternative alleles 
(e.g. C or T) of the inherited SNP or de novo mutation, and one universal primer placed some 50-
100bp distal to the de novo mutation (or the inherited SNP, Figure 2).  
 
 
 
 
 
The PCR2 was more efficient on the DNA strand that carried the allele complementary to the primer 
sequence (the C or T allele), and therefore the sequencing trace was higher for the allele at the de 
novo site, which was on the same strand. This was visible on the sequence trace (Figure 3).  
 
 
 
 
 
 
Following this process the parent of origin of de novo  SNV is determined. 
 
 
  
Figure 3. Sequencing of allele-specific PCR product for allele 
T (A) and allele C (B). The position of the SNP is shown with 
red arrow. Allele T of  the inherited SNP is on the same 
strand as allele  A from the de novo mutation (T as 
sequenced in reverse direction), because in the allele-
specific PCR product for allele T of the inherited SNP,  allele  
T (red peak) from the de  novo  mutation is preferentially 
amplified Figure 2A). The opposite applies for the alternative 
allele (Figure 2B) 
Figure2: Two-stage PCR amplification.  Stage 
1, a product that encompass both the 
inherited and the de novo SNP is obtained. 
Stage 2, this product is used for allele-specific 
amplification followed by sequencing. 
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CHAPTER THREE: MATERIALS, METHODS AND RESULTS 
 
 
 
3.1 PRIMERS  
 
 
3.1.1 PRIMERS DESIGN 
 
UCSC GENOME BIOINFORMATICS 
 
In order to design the primers, first of all, the DNA was obtained, including the de novo  SNV and the 
proxy SNP, with 500 bp upstream and downstream, in order to have enough place to find proper 
primers. For that, the UCSC Genome Bioinformatics website (http://genome.ucsc.edu/) was used. 
 
Once the Fasta sequence was obtained,  the previous step was repeated adding 5bp upstream and 
downstream in order to find the exact position of the de novo SNV and the proxy SNP. 
Note: These are the colours I used along the project to identify them. 
 
 
PRIMER 3 
 
Once  the sequence in FASTA is  labelled with the specific colours,  the part of the sequence that I 
wanted to be part of the product of the 1st PCR was included inside brackets “*...+”, so the 
programme PRIMER 3 (http://frodo.wi.mit.edu/) could find the primers including that region. 
 
In order to chose the best pair of primers from the list proposed by PRIMER3 they had to follow 
these rules: 
 
- The primer that will be used for sequencing (the one opposite to the allele-specific one) 
should be located between 100 and 150 bp from the de novo SNV or the proxy SNP.  
- Temperature: Forward and Reverse primers should have the same Temperature. 
- Length: around 20 bp 
- GC content: 50% or more hybridizes better with the sequence. 
- Avoid self complementary  
- Any: 3 or 4 is OK, when higher the number, there are more probabilities that it 
hybridizes between them or in another part. 
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- Max self complementary: less than 5, and we will also check it in another program Dobril 
Primer. 
- Avoid poly-A, as the sequencing will not work properly 
 
If the any of the primers showed was good enough, I had to create one that followed the rules.  
 
 
DOBRIL PRIMER 
 
In order to check for the self complementary of the primer, the DOBRIL PRIMER application 
(http://m034.pc.uwcm.ac.uk/FP_Primer.html) was used, where the polymorphism we wanted to 
target had to be between brackets. Once the primer was submitted, a list of the possible primers 
similar to it, and a dG(kCal/mol) value was given. We decided not to accept any primer with a dG 
above І3І.  
 
The Dobril Primer also showed the opt str. 
 
 
 
 
 
And the most important, was to make sure the 1st PCR primers didn’t hybridize in other parts of the 
genome. To check that, the tool BLAST or IN SILICO PCR, from the UCSC Genome Bioinformatics 
website was used. 
 
 
 
2nd PCR PRIMERS 
 
 
 
In order to create the primers for the 2nd PCR, there were two options: 
o The Forward primer contained the first SNV (2)+ Reverse primer from PCR1 
o The Reverse primer contained the last SNV (2) + Forward primer from PCR1 
*2: means that there are 2 primers specific for the SNV (one containing the 
reference and the other the alternative) 
 
In order to increase specificity: 
o Another mismatch was introduced in the allele-specific primers. 
Changing T<>G and C<>A. 
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We only wanted to amplify the concrete allele with the mutation, so introducing the mismatches, we 
made sure that it would hybridize correctly.  
 
Sometimes, some of them weren’t specific enough, and in order to increase specificity, we had to 
dilute more the 1st PCR product, reduce the number of cycles, etc. 
 
 
SET 1 (16 de novo + proxy SNP) 
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SET 2 (24 de novo + proxy SNP) 
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3.1.2 WORKING DILUTIONS 
 
Once the primers arrived, with its technical datasheet, the process could be started. 
 
 
 
 
 
 
In a new plate, I prepared the primer dilutions. The cross (X) in the following table refers to the 
primer I used for the 2nd PCR and the Sequencing. 
 
1 2 3 4 5 6 7 8 
A 
 
x 
 
  x 
   B x 
  
  x 
   C x 
  
  x 
   D x 
  
  
 
x 
  E 
 
x 
 
  
 
x 
  F 
 
x 
 
  
 
x 
  G 
 
x 
 
  x 
   H 
 
x 
 
  x 
   
 
F R AS1 AS2 F R AS1 AS2 
 
In the following table the working dilutions are showed. For PCR1 : Forward + Reverse, PCR2: AS1 + 
Forward or Reverse; AS2 + Forward or Reverse,  SEQUENCING: Forward or Reverse. Diluted with 
ultrapure water. 
 
 
1 2 3 4 5 6 7 8 9 10 
A 
 
          
 
      
B 
 
          
 
      
C 3 µL P1 3µL P3 3µL P4       3 µL P5 3µL P7 3µL P8   
D 3µL P2 
3µL PX 
(1/2) 
3µL PX 
(1/2) 
3µL PX 
(1/2)     3µL P6 
3µL PX 
(5/6) 
3µL PX 
(5/6) 
3µL PX 
(5/6) 
E 95µL H20 95µL H20 95µL H20 97µL H20     95µL H20 95µL H20 95µL H20 97µL H20 
F 
 
          
 
      
G 
 
          
 
      
H 
 
          
 
      
 
PCR1 PCR2 SEQ     PCR1 PCR2 SEQ 
 
Table 3: SIGMA datasheet with the plate layout for the first set of primers (1-16).  
F: Forward  R: Reverse  AS: Allele-Specific 
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For the second set of primers, the same procedure was followed although instead of for 16, for 24 
de novos with its proxy. 
 
Working dilutions for SET 2: 
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3.2 POLYMERASE CHAIN REACTION (PCR) 
 
The Polymerase Chain Reaction allowed us to amplify selectively our specific target DNA sequence 
within the total genomic DNA of each patient. 
For the PCR, polymerase chain reaction buffer, forward and reverse oligonucleotide primers, 
deoxynucleotide (dNTP) mix, sterile molecular grade water, and DNA polymerase were needed. PCR 
reactions were carried in a final volume of 16 µL. Enzyme used was Taq polymerase, and PCR was 
performed on 4ng of DNA. 
 
 1x x 
Buffer 1.2  
200 mcM dNTPs  x4 1  
TaqQ 0.06  
H2O 3.74  
   
DNA = 4µL   
Primers mix = 2 µL   
PCR mix volume = 10µL   
 
The dNTPs were previously prepared to a final concentration of 5mM all. 
 
dNTPs  (100mM/each)  dNTPs (1.25mM/each) 5mM/all  
dATPs  12.5µL A  
dGTPs For PCR  12.5µL G + 950 µL H2O 
dCTPs  12.5µL C  
dTTPs  12.5µL T  
 
 
    
3.2.1 OPTIMISATION OF THE 1ST PCR 
 
 
Different PCR programmes were run in order to optimise the Polymerase Chain Reaction and obtain 
a good product. All of them followed the following conditions, and in order to find the proper 
specific conditions for each set of primers, little variations were introduced between them. The 
extension time also needed to be modified depending on the length of the PCR products (1 min each 
1000bp). 
 
 
PCR   
Denature 95 °C  
Annealing 50-67 °C  
Extension 72 °C 1min/1kb 
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To summarise, the programs that worked better are the following ones: 
 
For the 1ST SET, both HS58TD30 (Touch down from 62 degrees to 58 for the annealing temperature, 
and 30 cycles extension then) and TCHD5560 (Touch down from 60 to 55, and 40 cycles extension) 
worked properly for the 1st PCR, although the second one worked better (elongation time of 1 min).  
 
 
 
 
For the 2ND SET (24 more de novos with its proxy), the extension time was increased to 3min, as the 
biggest fragments were of 3kb. In this case, the HS58TD30L worked better, as with the other one, 
unspecific products appeared (probably because the touchdown of the first one jumped from 2 
degrees, which increased specificity).  
 
But anyway, 8 of 24 genes 
failed (labelled in yellow), and 
the rest of them, at the end of 
the process the sequencing 
results weren’t really clear.  
 
In order to find the specific 
conditions in which the 
primers would work properly, 
all the primers were run with 
other DNA samples at 60 
degrees as the annealing 
temperature.  
They worked better, only failed 
for a few genes.  
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For the ones that failed a Gradient PCR, (where in each column the annealing temperature was 
different) was run, and the proper temperature for the genes that didn’t work at 60 degrees was 
found. 
 
For the next sets, the best would probably be to run all of them at 60 degrees in the first time. And 
probably with other DNA samples first, so the patient’s DNA is not wasted. 
 
In the following table, the best temperature for each primer is showed. 
 
Gene # Annealing T°C  Gene # Annealing T°C 
1 60  13 - 
2 60  14 - 
3 60  15 60 
4 55-57  16 60 
5 60  17 60 
6 60  18 60 
7 60  19 60 
8 68  20 - 
9 55  21 60 
10 60  22 64 
11 60  23 60 
12 60  24 60 
 
 
Finally, we run for the 1st PCR of the 2nd set, with the patient’s samples, with these conditions and 
programs: 
 
 
For most of them at 60 degrees  HS603 
 2 TD from 64 to 62, 3 cycles each, and then at 60 35cycles. 
For 4 and 9 at 55 degrees HS553 
 Without TD, at 55 degrees 30 cycles. 
For 8 at 68 degrees  HS683 
 Without TD, at 68 degrees 30 cycles. 
For 22 at 64 degrees  HS643 
 Without TD, at 64 degrees 30 cycles. 
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3.3 ALLELE SPECIFIC PCR 
 
 
For the allele specific PCR, oligonucleotide primers were designed so as to discriminate between 
target DNA sequences that differ by a single oligonucleotide in the region of interest. The primers 
were designed to differ in the at the nucleotide that occurs at the extreme 3’ terminus, because the 
DNA synthesis step in a PCR reaction is crucially dependent on correct base pairing at 3’end. Under 
stringent conditions, a mismatched primer doesn’t initiate replication, whereas a matched primer 
does. The appearance of an amplification product therefore indicates the genotype. 
 
The reagents and DNA used were the same and in the same concentrations as for the 1st PCR and in 
the same concentrations. The primer mix used was the specific for the 2nd PCR. 
 
3.3.1 OPTIMISATION OF THE 2ND PCR 
 
For the set1, the same programs as for the first PCR: HS58TD30, TCHD5560 were run, and also with a 
variation of the second one, reducing the number of cycles to 12. From the sequencing data, only a 
few of them worked properly and I was able to see the phase of the de novo mutation for them, for 
the others, the primers weren’t specific enough, so both sequences were amplified (it didn’t 
discriminate). 
 
In order to increase the specificity of the primers, dilutions of the 1st PCR product  were necessary 
(15x dilution wasn’t enough, so finally, another 10x dilution more was needed).  
 
Running the programme with only 12 cycles (TD556012) wasn’t enough, (the 2nd PCR product that 
we can see from the gel was too poor) but the final dilution was ideal as the primers were specific 
(the few that work discriminate between the alleles, I could see the phase and determine the 
parental origin of them).  
The balance between having too much product ( we cannot discriminate the phase of the mutation 
with the proxy when sequencing) and too less (we don’t know if it didn’t work or if it wasn’t enough 
cycles) needed to be found. 
 
 
Reading some papers, we saw that some groups did straight away the allele specific-specific PCR 
(without a previous  1st PCR ), So we also did it that way, because if we could avoid to do the 1st PCR, 
we would be able to safe in money and time. The AS-PCR with the programe TD556030 (30 cycles 
instead of 40) was set, but it didn’t work properly, only for a few genes, which wasn’t enough. 
 
Finally, the 2nd PCR was set up, after diluting the 1st PCR product twice, and with the programme 
TD556020 and TD556030 (which are a variation of the original TCHD5560, now with 20 and 30 
cycles). 
 
After cleaning up the 2nd PCR product, preparing for the sequencing, cleaning up the product and 
sequencing, the results were ideal! With these conditions and the parental origin for them could be 
determined.  
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3.4 AGAROSE GEL ELECTROPHORESIS  
 
 
Agarose gels were made as 2% agarose in 1x TAE buffer (40mM Tris-acetic acid, 10 mM EDTA pH 
8.0). The agarose was dissolved in TAE by heating in the microwave oven on full power for 1.30 min, 
and cooled to 50 degrees C. Ethidium bromide solution was added (2 µL into 100 mL), and the gel 
solution was poured into a gel former with a comb inserted.  
 
When set, the comb was removed, the gel transferred to an electrophoresis tank, and 1x TAE added 
to cover the surface off the gel. Samples were first mixed with 6x gel loading buffer (30% (v/v) 
glycerol, 20 mM EDTA ph 8.0, 0.25% (w/v) bromophenol blue, 0.25% (w/v)  xylene cyanol in water) 
and located in the wells. A 1kb Plus DNA Ladder was loaded  when needed beside the sample and 
used as a size marker. 
 
The gel was run at 100v for approximately 30 min. Ethidium bromide stained nucleic acid was 
visualised using a transilluminator system. 
 
 
 
 
 
Figure 4.  
Allele-Specific PCR product are checked 
in the agarose gel. Two different 
programmes were run, TD556020 and 
TD556030 (variations in the number of 
cycles of the original TCHD5560, 
decreasing to 20 and 30 cycles instead 
of 40). These PCR products correspond 
to Set 1 final result, after applying the 
proper conditions in order to 
determine the parental origin of each 
of the 16 de novo of that set. 
 
Table 3.  
Set 1 plate layout sent to sequence. 
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3.5 PURIFICATION OF PCR PRODUCTS 
 
If the PCR worked, the PCR products were cleaned in order to carry on the process. The leftover 
primers and the P of the dNTPs needed to be removed. Exonuclease I and Shrimp Alkaline 
Phosphatase were used for that. 
 
 1x 
SAP 0.5 µL 
Exonuclease I 0.1 µL 
Water 4.4 µL 
 5 µL 
 
 
 
3.6 SEQUENCING REACTION 
 
 
In the Sanger method (chain terminator sequencing, dideoxychain termination method), the DNA 
strand to be analysed is used as a template and primed with an oligonucleotide. In the sequencing 
reaction, the DNA polymerase will extend from the 3'-OH end of the sequencing primer to generate 
complimentary strand in the presence of a mixture of four naturally occurring deoxynucleotides and 
one of them being a dideoxynucleotide which can not bind other deoxynucleotides because its 3' 
end is modified.   
An improved approach called 'dye terminator sequencing' uses each of the dideoxynucleotide chain-
terminators labeled with a separate fluorescent dye, which fluoresces at a different wavelength 
instead of labeled primers.  This approach leads to a complete sequence in a single reaction, rather 
than the four needed with the labeled-primer approach. 
  
The four bases are detected using different fluorescent labels. These are detected and represented 
as 'peaks' of different colours that can then be interpreted to determine the base sequence. 
 
In order to obtain the product for sequencing, sequencing buffer, big dye, purified water, the 
forward or the reverse primer and the cleaned product of the 2nd PCR will be mixed and run in the 
programme called SEQUENCE in the thermocycler. 
 
 
 
 
 
 
 
Programme: SAP 
1h 37 °C 
20’ 80 °C 
5’ 95 °C 
∞ 12 °C 
SEQUENCING MIX 1x  
Big dye 0.25 µL 
Water 0.875 µL 
Seq buffer 1.875 µL 
  
Total seq mix 3 µL 
Primer  2 µL 
Cleaned PCR prod 5 µL 
Programme: SEQUENCE (2h) 
1 2’ 96 °C 
2 10’’ 96 °C 
3 5’’ 50 °C 
4 4’ 60 °C 
5 GO TO 2 25x 
6 ∞ 15 °C 
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3.6.1 PURIFICATION USING THE ROBOT 
 
 
Sequencing reactions need to be cleaned up prior to injection 
on the ABI 3100 sequencer in order to remove both the 
unincorporated dideoxynucleotides as well as salts from the 
reaction buffers. The cleaning up protocols was performed 
with the robot BIOMEK NX. 
 
The reagents needed were the Agencourt CleanSEQ, ethanol 
and purified water, and the protocol used CleanSeq.96.2.40 
 
 
 
 
 
 
 
3.6.2 ABI 3100 SEQUENCER 
 
Each product generated will carry a fluorescent molecule at one extremity. After cleaning, the 
sequences are resuspended in loading buffer and run on the capillaries. A laser detects the passage 
of the fluorescent products and transmits this information to the computer, which will generate a 
text file and a chromatogram where T appears in red, G in black, C in blue, and A in green. To read 
the sequencing data the Sequence Scanner (Applied Biosystems) was used. 
 
   
After sequencing the allele-specific PCR product, we were able to distinguish the phase of each  de 
novo SNV with the proxy SNP.  The position of the SNP is showed with red arrow. (See 2.3 
Determining the parent of origin of de novo  mutations). 
 
Figure 5. Process Overview. 1. Add Agencourt CleanSEQ reagent and ethanol to 
sequencing reaction 2. Bind sequencing products to magnetic beads 3. Separate 
sequencing products from contaminants with magnetic field 4. Wash with ethanol 5. 
Elute from magnetic particles 6. Transfer away from magnetic beads 
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CHAPTER FOUR:  OUTCOMES AND BENEFITS  
 
 
 
4.1 FINAL RESULTS 
 
 
Working in the project IDENTIFYING THE PARENT-OF-ORIGIN OF DE NOVO SNVs IN SCHIZOPHRENIA I 
was able to screen for proxy SNPs for each called de novo SNV, from a huge dataset with the NGS 
information, and create a list of them. That first step of the project required a lot of time, but it had 
to be done in order to have an informative SNP within 5kb next to the de novo in order to perform 
the Allele-Specific PCR and sequence to read the parent of origin of each.  
 
Once the list was created, I grouped them depending on the size (from 1kb to 5kb), and after 
learning how to design and select the best primers (depending on different parameters as length, 
temperature, self-complementarily, GC content...) using programmes such as UCSC, Primer3 and 
Dobril primer, I designed the primers for them. 
 
Before starting working with the proper samples, I did a previous set up of the method with 2 other 
primers with non precious samples, and that helped to obtain a closer idea of which PCR 
programmes were working better. Anyway, along the project, I learned that different variations 
were always needed to be introduced, and that depending on the product size and in each primer, 
modifications  in the programmes were needed (annealing temperature, extension time...), the same 
happened with the dilution of the product. For this reason, the optimisation of the method (the set 
up) was needed to be done for each set of primers.  
 
For the 1st set, after changing different parameters, the best conditions were: 
 1st PCR: The PCR programme TCHD5560, which had 5 steps of touch down, with the 
annealing temperature decreasing from 60 degrees to 56, and then, 40 cycles at 55 degrees. 
The denaturing temperature was 95 degrees during 30 seconds, the annealing temperature 
with the touch down from 60 to 55 during 45’ and finally, the extension step was at 72 1min 
(as the product size of the fragments were 1kb).  
 Before the second PCR, in order to obtain a clear sequencing data, the 1st PCR products 
needed to be diluted twice, 15x and 10x. 
 2nd PCR: The PCR programme TD556020 or TD556030 were the best, wich follow the same 
steps as the original TCHD5560, but instead of 40 cycles, 20 and 30. 
 For the clean up, and the sequencing reaction, I always used used the programs SAP-EXO 
(after the PCRs) and with the robot the CleanSeq (after sequencing reaction) in the thermo 
cycler. Working with the robot Biomak NX it was also a great experience as it was the first 
time, and I felt comfortable using it. 
 
 
For the 2st set, which fragments were up to 3kb, the optimisation was more complicated. To start 
with, I tried with the same programmes that worked for the 1st set, but changing the extension time. 
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Although only a few of them didn’t work, I carried on with all of them, following the same process as 
for the Set 1, but the sequencing results weren’t good. We wanted to obtain better results, so I tried 
changing the annealing temperature to 60 degrees, as most of the primers were going to work 
better in such conditions. And then, for the ones that didn’t at 60, a gradient PCR.  
 
After changing different parameters, the best conditions for the 1st PCR were: 
For most of them at 60 degrees with the programme HS603 (2 TD from 64 to 62, 3 cycles each, and 
then at 60 35cycles). And for the rest:  two with the programme  HS553 (Without TD, and at 55 
degrees 30 cycles), one with HS683 (Without TD, and at 68 degrees 30 cycles), and another one with 
HS643 (Without TD, and at 64 degrees 30 cycles). 
 
 
With the second set I didn’t obtain final results as I had to submit the project. But  the sequencing 
data was very clear and discriminate for 10 of the 16 genes from the set 1, and I was able to work 
out the phase of the de novo with the proxy, and find the parental origin of the de novo SNV (3 
maternal : 7 paternal).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moreover, in a previous pilot laboratory experiment performed by this group, they called the the 
parent-of-origin (2 maternal : 6 paternal) of 8 cases.  
 
These results prove that although specific variations are needed in the set up, the method is valid to 
determinate the parent of origin of de novo mutations, and if we add both results obtained, for the 
moment, the parent-of-origin of de novo mutations is: 5 maternal: 13 paternal.  
 
  
# GENE Parent of Origin 
1 ZNF847P M 
2 HPS3 P 
3 VCAN M 
4 BCAT2 M 
5 TLR3 P 
6 SPTBN5 Failed PCR 
7 YTHDC1 Not discriminate 
8 DOLPP1 Failed PCR 
9 LIMD1 P 
10 TBC1D4 P 
11 OR5H1 P 
12 TAF1C Failed PCR  
13 EPHB3 P 
14 AKT1 P 
15 FGFR3 Failed PCR 
16 ALDH1L1 Not discriminate  
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4.2 CONCLUSIONS 
 
 
Identifying the mechanisms of mutation formation in humans is of a great theoretical value in 
genetics and medicine. De novo mutations are important both as sources of diversity in evolution 
and for their immediate impact on diseases.  
Establish the parental origin of up to 600 de novo mutations (about 60% of 1000 de novos) will be a 
long-term project. Although I was only able to determine the parent of origin of 10 de novo SNV (3 
maternal:7 paternal), plus 8 other established in a previous study (2maternal:6paternal), once this 
study is finished, an accurate ratio for maternal:paternal origin of de novo SNPs found in SZ trios will 
be established and will also allow to perform correlations between the rate of such mutations and 
paternal age.  
 
The results obtained with the main project (in which this one is involved) will have great prognostic 
value and can be implemented in the mental health prevention programs. In order to advice the 
families about the increase of risk with the paternal age (once the hypothesis is proved) at the time 
of conception of the child, and reduce the number of schizophrenia cases in the future generations. 
 
Once this project is finished, more information about the different type of mutations related with 
schizophrenia will be available. The evidence for the involvement of these de novo mutations will 
also offer a new approach to detect potentially pathogenic variants and may help to explain partially 
the causes and inheritance pattern of SZ and also how SZ prevalence remains stable in the general 
population despite low fecundity. This will provide a better understanding of the mechanism 
underlying this complex disease, and will help us to be a step closer in order to find key targets for 
therapeutic approaches.  
 
 
FUTURE DIRECTION 
 
The relationship between genotype and phenotype in schizophrenia is likely to be mediated by 
complex causal pathways involving gene-gene and gene-environment interactions. 
 
At present, no single, or major, environmental risk factor influencing the incidence of schizophrenia 
has been conclusively demonstrated. Further studies using large samples are required to evaluate 
potential risk factors, antecedents, and predictors for which the present evidence is inconclusive.  
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